Evidence map›Paper›PMID 28338639›Full record

ReviewNutrients2017

Beyond the Cholesterol-Lowering Effect of Soy Protein: A Review of the Effects of Dietary Soy and Its Constituents on Risk Factors for Cardiovascular Disease.

D Dan Ramdath, Emily M T Padhi, Sidra Sarfaraz, Simone Renwick, Alison M Duncan

Registry-linked trialAbstract readReview
In one paragraph

Review in Nutrients, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07175766 (A Study on the Lipid-Modulating and Health Benefits of Dachundou No Sugar Added Soymilk in Humans), which is not on this map. Cited by 85 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
85citing papers in PubMed, 7 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07175766 nacompletednot on this mapstarted 2025, after this paper: background citation

A Study on the Lipid-Modulating and Health Benefits of Dachundou No Sugar Added Soymilk in Humans

TypeinterventionalSponsorNational Taiwan Sport UniversityRan2025 to 2026Enrolled25ConditionsDyslipidemias, Hypercholesterolemia, Cardiovascular DiseasesArmsDachundou No Sugar Added Soymilk
3 · Its place in the literature

Who cites it

85 citing papers in PubMed, 7 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Effects ofFood chemistry: X · 2024
    Article
  19. Article
  20. Lecithin and cardiovascular health: a comprehensive review.The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology · 2024
    Review

25 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

D Dan RamdathGuelph Research and Development Centre, Agriculture and Agri-Food Canada, Guelph, ON N1G 5C9, Canada. dan.ramdath@agr.gc.ca.
Emily M T PadhiGuelph Research and Development Centre, Agriculture and Agri-Food Canada, Guelph, ON N1G 5C9, Canada. epadhi@gmail.com.
Sidra SarfarazGuelph Research and Development Centre, Agriculture and Agri-Food Canada, Guelph, ON N1G 5C9, Canada. sidra9518@gmail.com.
Simone RenwickGuelph Research and Development Centre, Agriculture and Agri-Food Canada, Guelph, ON N1G 5C9, Canada. srenwick@mail.uoguelph.ca.
Alison M DuncanDepartment of Human Health and Nutritional Sciences, University of Guelph, Guelph, ON N1G 2E1, Canada. amduncan@uoguelph.ca.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The hypocholesterolemic effect of soy is well-documented and this has led to the regulatory approval of a health claim relating soy protein to a reduced risk of cardiovascular disease (CVD). However, soybeans contain additional components, such as isoflavones, lecithins, saponins and fiber that may improve cardiovascular health through independent mechanisms. This review summarizes the evidence on the cardiovascular benefits of non-protein soy components in relation to known CVD risk factors such as hypertension, hyperglycemia, inflammation, and obesity beyond cholesterol lowering. Overall, the available evidence suggests non-protein soy constituents improve markers of cardiovascular health; however, additional carefully designed studies are required to independently elucidate these effects. Further, work is also needed to clarify the role of isoflavone-metabolizing phenotype and gut microbiota composition on biological effect.

Indexed as

AnimalsAnticholesteremic AgentsBiomarkersCardiovascular DiseasesCholesterol, HDLCholesterol, LDLDietDisease Models, AnimalGlycine maxHumansIsoflavonesMeta-Analysis as TopicObservational Studies as TopicRandomized Controlled Trials as TopicRisk FactorsSatiationAnticholesteremic AgentsBiomarkersCholesterol, HDLCholesterol, LDLIsoflavonesSoybean ProteinsTriglyceridescardiovascular diseasecholesterolDietary soyfunctional foodsisoflavoneslipidsobesitysoy protein

Identifiers

PMID28338639
PMCPMC5409663

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.